View all Webinars

Schwegman Lundberg & Woessner

Close     Close Mobile Menu

#9 - Biosimilars: Patentable Approaches and Surveillance

Are Biosimilars fast becoming the same as pharmaceutical generics; lowest cost and lowest price wins? Is there really a benefit to copying a sponsor’s biological product or are there other ways to fast track FDA approval of your competitive biological product without the need to engage in the Biosimilar dance?

Watch this webinar with Schwegman attorney, Jim Nelson –

Download Slides

  Back to All Resources